Cargando…
Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19
BACKGROUND: A randomized controlled trial involving a high-risk, unvaccinated population that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir was effective in preventing progression to severe COVID-19. Our objective was to evaluate the effectiveness of nirmatrelvir...
Autores principales: | Schwartz, Kevin L., Wang, Jun, Tadrous, Mina, Langford, Bradley J., Daneman, Nick, Leung, Valerie, Gomes, Tara, Friedman, Lindsay, Daley, Peter, Brown, Kevin A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928441/ https://www.ncbi.nlm.nih.gov/pubmed/36781188 http://dx.doi.org/10.1503/cmaj.221608 |
Ejemplares similares
-
2277. Variability in Changes in Physician Outpatient Antibiotic Prescribing from 2019 to 2021 during the COVID-19 Pandemic in Ontario, Canada
por: Tandon, Pranav, et al.
Publicado: (2023) -
Variability in changes in physician outpatient antibiotic prescribing from 2019 to 2021 during the COVID-19 pandemic in Ontario, Canada
por: Tandon, Pranav, et al.
Publicado: (2023) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022) -
Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)